In a pioneering medical breakthrough, a team of researchers in China has successfully cured a patient’s type 2 diabetes using an innovative cell therapy approach. The achievement, reported in the journal Cell Discovery on April 30, is the first-ever instance of a diabetes cure through cell transplantation.
The patient, a 59-year-old man, had been battling type 2 diabetes for 25 years. Despite undergoing a kidney transplant in 2017, his condition deteriorated, leading to a significant decline in pancreatic islet function – the cells responsible for producing insulin and regulating blood sugar levels. As a result, he became heavily reliant on multiple daily insulin injections, putting him at high risk of life-threatening complications.
In July 2021, the team led by researcher Yin Hao at Shanghai Changzheng Hospital initiated an experimental treatment. They utilized the patient’s peripheral blood mononuclear cells and programmed them into “seed cells” which are capable of reconstituting pancreatic islet tissue in an artificial environment.
Within just 11 weeks after the cell transplant, the patient no longer required external insulin injections. Over the following year, he gradually reduced and eventually discontinued all oral medications for blood sugar control. Follow-up examinations revealed that his pancreatic islet function had been effectively restored, allowing him to maintain normal blood glucose levels without any medical intervention.
However, further studies involving more patients are needed to validate these findings and explore the long-term efficacy of this groundbreaking cell therapy.
An estimated 422 million people worldwide are affected by diabetes. In China alone, where the study was conducted, approximately 140 million individuals live with diabetes, with 40 million relying on lifelong insulin injections. The successful application of this cell therapy could significantly reduce this burden and improve the quality of life for countless patients.
Copyright @smorescience. All rights reserved. Do not copy, cite, publish, or distribute this content without permission.
